Volume 9.33 | Aug 25

Cell Therapy News 9.33, August 25, 2008
     In this issue: Science | Policy | Business | NIH | CBER | Regulatory
Cell Therapy News on Facebook  Cell Therapy News on Twitter

Top Stories

Clinical-Scale Generation of Functional Red Blood Cells from Human Embryonic Stem Cells: Advanced Cell Technology, Inc. reported that it is feasible to differentiate and mature human embryonic stem cells into functional oxygen-carrying red blood cells under conditions suitable for scale-up.

Immune Response to Human Embryonic Stem Cells in Mice Suggests Human Therapy May Face Challenge: Human embryonic stem cells trigger an immune response in mice, which suggest that the effectiveness of human therapies derived from the cells could be limited unless ways are found to dampen the rejection response.


The TriMark Stem Cell Conference 2008
October 20, 2008  |  San Francisco, California
Enter “CONNEXON” at checkout and receive 10% off registration. 
Click here to register today.

University of California Riverside Researcher Develops Non-Animal-Based Method to Grow Human Embryonic Stem Cells
A University of California Riverside researcher has developed a new method, which is not only cleaner and easier to use than conventional methods of culturing hESCs but also results in hESCs whose pluripotency is uncompromised.

RNA Experiments Could Lead to New Treatments for Neuroblastoma
University of Texas Medical Branch at Galveston researchers describe cell-culture and animal experiments that demonstrate how shutting down a single biochemical signaling connection dramatically suppresses neuroblastoma tumor formation and slows the cancer’s spread.

Hydrogels Provide Scaffolding for Growth of Bone Cells
Hyaluronic hydrogels developed by Carnegie Mellon University researchers may provide a suitable scaffolding to enable bone regeneration.

Japanese Researchers Create Stem Cells from Wisdom Teeth
Researchers at the government-backed National Institute of Advanced Industrial Science and Technology said they created stem cells of the type found in human embryos using the removed wisdom teeth of a 10-year-old girl.


Allogeneic Endometrial Regenerative Cells: An “Off the Shelf Solution” for Critical Limb Ischemia?
Researchers using cells obtained from menstrual blood, termed ‘endometrial regenerative cells’ were capable of restoring blood flow in an animal model of advanced peripheral artery disease.

Therapeutic RNAi Targeting PCSK9 Acutely Lowers Plasma Cholesterol in Rodents and LDL Cholesterol in Nonhuman Primates
Here, the researchers have developed active, cross-species, small interfering RNAs capable of targeting murine, rat, nonhuman primate, and human PCSK9. These results pave the way for the development of PCSK9-lowering agents as a future strategy for treatment of hypercholesterolemia.

The Effect of Controlled Growth Factor Delivery on Embryonic Stem Cell Differentiation Inside Fibrin Scaffolds
The goal of this project was to develop 3-D biomaterial scaffolds that present cues to direct the differentiation of embryonic stem cell-derived neural progenitor cells, seeded inside the scaffolds, into mature neural phenotypes, specifically neurons and oligodendrocytes.


Cellular Therapy Laboratory Manager

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Click here to post your career opportunities.


Stem Cell Board Members Should Attend Meetings or Resign, Consumer Group Says
Frequently facing difficulties mustering a quorum for meetings, California’s stem cell oversight board has five members who showed up for 40 percent or fewer of regular board meetings so far this year, an analysis of attendance records by Consumer Watchdog found.

Slowdown in The National Institutes of Health Funding Creates ‘Quiet Crisis’
Five straight years of flat funding from the National Institutes of Health have Washington University and Saint Louis University scrambling to fill financial gaps with other funding sources to keep biomedical research projects going.


STEMCELL Technologies Introduces AggreWell(TM)400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
STEMCELL Technologies recently announced the release of the AggreWell(TM)400 plates, a revolutionary tool for researchers using embryonic and induced pluripotent stem cells.

MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides
MDRNA, Inc. announced recently that it has signed an exclusive license agreement to intellectual property from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids.

ArunA Biomedical Announces Exclusive Worldwide Technology License Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
ArunA Biomedical, Inc., announced recently that it has entered into an exclusive worldwide technology licensing agreement with the University of Georgia Research Foundation that will enable the company to commercialize human mesenchymal cells developed at the University of Georgia.

Medinet Starts Commercialization of Novel Cancer Immunotherapy Technology in Japan Utilizing Maxcyte’s Cell Loading System
MaxCyte, Inc. and Medinet Co., Ltd. announced recently that Medinet will begin commercializing a novel cell engineering approach, utilizing MaxCyte’s cell loading technology, on its cancer immunotherapy services in Japan.

International Stem Cell Corporation Arranges $3 Million Equity Financing
International Stem Cell Corporation has entered into a subscription agreement with an accredited investor to sell $3,000,000 of Series C Preferred Stock at a price of $1.00 per share.

Genentech to Pay Retention Bonuses
Genentech said Thursday that it would spend up to $371 million on retention bonuses to keep its employees from leaving because of the possible acquisition of the company by its majority shareowner, Roche.


The National Institutes of Health Creates New Stem Cell Research Center
The National Institutes of Health told staffers last week that it is setting up a bone marrow-stem cell transplant center within the National Institute for Arthritis and Musculoskeletal and Skin Diseases.

Delays in Grant Application Submission due to Tropical Storm/Hurricane Fay

National Institute of Arthritis and Musculoskeletal and Skin Diseases Building Interdisciplinary Research Team Revision Awards (R01)


Substantially Equivalent 510(k) Device – Cymbal Automated Blood Collection System – Haemonetics Corp

Substantially Equivalent 510(k) Device – TANGO OPTIMO Automated Blood Bank Analyzer System

Product Approval Information – Blood Grouping Reagent

Product Approval Information – Reagent Red Blood Cells; Reagent Red Blood Cells For Use in Automated Systems



Blood Products Advisory Committee

Supplemental Applications Proposing Labeling Changes for Approved Drugs, Biologics, and Medical Devices

 Learn more about Cell Therapy News:  Archives  |  Events  |  Update Profile  |  Contact Us